Biotech
-
Lexicon’s Volatility Could Be Your Friend After The Zynquista Rejection
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is an organization identified for locating novel drug targets and drug candidates developed from state-of-the-art medicinal…
Read More » -
Aerie Pharmaceuticals Delivers Mixed Result; Focus On International Expansion
Durhan, NC: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a scientific stage pharmaceutical firm targeted on offering therapies for the therapy of eye-related…
Read More » -
Tackling triple-negative breast cancer by blocking 2 key survival pathways
[ad_1] Triple-negative breast cancer is the hardest type of the illness to deal with as a result of it lacks…
Read More » -
J&J takes stake in Locus’ CRISPR-based ‘Pac-Man’ antimicrobials
[ad_1] Just over a yr after its first-round financing, CRISPR firm Locus Biosciences has signed up Johnson & Johnson as…
Read More » -
LHC Group to Present at 37th Annual J.P. Morgan Healthcare Conference Nasdaq:LHCG
[ad_1] LAFAYETTE, La., Jan. 03, 2019 (GLOBE NEWSWIRE) — LHC Group, Inc. (NASDAQ: LHCG) introduced as we speak that the…
Read More » -
Ex-Novartis Oncology CEO Barrett joins UroGen
[ad_1] Ex-Novartis Oncology CEO Liz Barrett has joined UroGen Pharma. Barrett is taking on as CEO of the uro-oncology specialist…
Read More » -
Amedisys to Present at the 37th Annual J.P. Morgan Healthcare Conference Nasdaq:AMED
[ad_1] BATON ROUGE, La., Jan. 02, 2019 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), one among America’s main residence health…
Read More » -
-390x220.jpg)
After 4 years, it’s a no from Sanofi as it punts MyoKardia drug program deal
[ad_1] French Big Pharma Sanofi is strolling away from a coronary heart drug illness pact with MyoKardia forward of knowledge…
Read More » -
Oxford Immunotec to Present at the 37th Annual J.P. Morgan Healthcare Conference Nasdaq:OXFD
[ad_1] OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a world,…
Read More » -
Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline
[ad_1] Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement…
Read More »
